Safe Use of Transdermal Clonidine Patches in the Management of Childhood Motor and Movement Disorders

Dear colleagues,

I am pleased to announce the publication of our latest position statement on the safe use of transdermal Clonidine patches in the management of childhood motor and movement disorders.

This position statement aims to provide healthcare professionals with pragmatic guidance on the use of transdermal clonidine in children with movement and motor disorders, including recommendations on when it is appropriate to consider initiation of transdermal patches; monitoring and advice to be provided to families and carers; and conversion back to enteral dosing.

I hope you will find this information useful.

Nanna Christiansen
Neonatal and Paediatric Pharmacy Group Chair

Keywords: Clonidine, transdermal, patch, movement disorder

Medicines for Children have also produced a leaflet ifor parents and carers:https://www.medicinesforchildren.org.uk/medicines/clonidine-patches-for-dystonia/

Position Statement

Keywords: Adrenaline Amiodarone Atracurium Clonidine Dinoprostone Dobutamine Dopamine Fentanyl Furosemide Heparin Insulin Labetalol Midazolam Milrinine Morphine Noradrenaline Rocuronium Vasopressin Vecuronium Infusions PICU NICU

NPPG Administrator, Suite 213, Boundary House, London  W7 2QE

Copyright © 2026 by Neonatal and Paediatric Pharmacy Group. All rights reserved. Website developed by Solo Films.